ES2145115T3 - Composiciones inyectables a base de derivados de taxanos. - Google Patents

Composiciones inyectables a base de derivados de taxanos.

Info

Publication number
ES2145115T3
ES2145115T3 ES94900881T ES94900881T ES2145115T3 ES 2145115 T3 ES2145115 T3 ES 2145115T3 ES 94900881 T ES94900881 T ES 94900881T ES 94900881 T ES94900881 T ES 94900881T ES 2145115 T3 ES2145115 T3 ES 2145115T3
Authority
ES
Spain
Prior art keywords
compositions based
taxanos
derivatives
injectable compositions
solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94900881T
Other languages
English (en)
Other versions
ES2145115T4 (es
Inventor
Jean-Marc Bobee
Lanty Patrick De
Gilles Guerin
Michel Veillard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9436137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2145115(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Application granted granted Critical
Publication of ES2145115T3 publication Critical patent/ES2145115T3/es
Publication of ES2145115T4 publication Critical patent/ES2145115T4/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Detergent Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVAS COMPOSICIONES A BASE DE TAXOIDES CONSTITUIDOS POR SOLUCIONES DE ESTOS DERIVADOS EN UN AGENTE TENSIOACTIVO. ESTAS SOLUCIONES SE UTILIZAN PARA PREPARAR SOLUTOS DE PERFUSIONES.
ES94900881T 1992-12-02 1993-11-26 Composiciones inyectables a base de derivados de taxanos. Expired - Lifetime ES2145115T4 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR92.14501 1992-12-02
FR9214501A FR2698543B1 (fr) 1992-12-02 1992-12-02 Nouvelles compositions à base de taxoides.

Publications (2)

Publication Number Publication Date
ES2145115T3 true ES2145115T3 (es) 2000-07-01
ES2145115T4 ES2145115T4 (es) 2010-06-17

Family

ID=9436137

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94900881T Expired - Lifetime ES2145115T4 (es) 1992-12-02 1993-11-26 Composiciones inyectables a base de derivados de taxanos.

Country Status (29)

Country Link
US (1) US5438072A (es)
EP (1) EP0671912B1 (es)
JP (1) JP3689791B2 (es)
KR (1) KR100330316B1 (es)
CN (2) CN1090170A (es)
AT (1) ATE190838T1 (es)
AU (1) AU691476B2 (es)
CA (1) CA2150576C (es)
CZ (1) CZ284080B6 (es)
DE (2) DE69328192T4 (es)
DK (1) DK0671912T3 (es)
ES (1) ES2145115T4 (es)
FI (1) FI113619B (es)
FR (1) FR2698543B1 (es)
GE (1) GEP19991856B (es)
GR (1) GR3032828T3 (es)
HK (1) HK1075197A1 (es)
HU (1) HU222833B1 (es)
MX (1) MX9306986A (es)
NO (1) NO314436B1 (es)
NZ (1) NZ258150A (es)
PL (1) PL174334B1 (es)
PT (1) PT671912E (es)
RU (1) RU2144356C1 (es)
SK (1) SK281558B6 (es)
TW (1) TW271395B (es)
WO (1) WO1994012171A1 (es)
YU (1) YU49092B (es)
ZA (1) ZA938936B (es)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435342D1 (de) 1993-07-19 2011-05-05 Angiotech Pharm Inc Anti-Angiogene Mittel und Verfahren zu deren Verwendung
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
CN1209059A (zh) * 1995-12-21 1999-02-24 基因实验室技术有限公司 紫杉烷类组合物及方法
KR100191446B1 (ko) * 1996-05-02 1999-06-15 송영욱 파클리탁셀 함유 전신성 홍반성 낭창치료제
DK0914102T3 (da) 1996-05-24 2006-01-09 Angiotech Pharm Inc Præparater og fremgangsmåder til behandling eller forebyggelse af syddomme i legemskanaler
KR100330373B1 (ko) * 1996-05-28 2002-11-07 주식회사한국신약 탁솔을 함유한 주사용 약제 조성물
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
CA2275889C (en) 1996-12-30 2008-03-18 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
BR9808697A (pt) * 1997-04-28 2000-07-11 Rhone Poulenc Rorer Sa Processo para inibir o crescimento de um tumor, vetor de adenovìrus defeituoso, vetor de vìrus, uso do mesmo, e, composição farmacêutica
CN1101677C (zh) * 1997-05-30 2003-02-19 韩万愚 含有紫杉醇的药用注射溶液
EP0998279B1 (en) * 1997-05-30 2002-10-16 Man Woo Han Pharmaceutical injection solution containing taxol
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
FR2794771B1 (fr) * 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2001035974A2 (en) * 1999-11-15 2001-05-25 Pharma Mar S.A. Aplidine treatment of cancers
US6638973B2 (en) * 2000-02-02 2003-10-28 Fsu Research Foundation, Inc. Taxane formulations
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
EP1337273A2 (en) * 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US20040241094A1 (en) * 2001-09-13 2004-12-02 Hesson Chung Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
US20050004012A1 (en) * 2001-10-19 2005-01-06 Ramon Mangues Use of aplidine for the treatment of pancreatic cancer
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
CN100341589C (zh) 2002-05-24 2007-10-10 血管技术国际股份公司 用于涂覆医用植入物的组合物和方法
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
CN102516417B (zh) 2002-09-06 2014-12-10 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
AU2004293030A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Electrical devices and anti-scarring agents
KR101203475B1 (ko) * 2004-09-22 2012-11-21 니폰 가야꾸 가부시끼가이샤 신규 블록 공중합체, 미셀 제제물 및 이를 유효성분으로함유하는 항암제
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
KR20080030024A (ko) 2005-06-17 2008-04-03 호스피라 오스트레일리아 피티와이 리미티드 도세탁셀의 약제학적 액상제제
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
KR20080106254A (ko) 2006-03-28 2008-12-04 니폰 가야꾸 가부시끼가이샤 탁산류의 고분자 결합체
US8940332B2 (en) 2006-05-18 2015-01-27 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
JP5548364B2 (ja) * 2006-10-03 2014-07-16 日本化薬株式会社 レゾルシノール誘導体の高分子結合体
EP2080779B1 (en) 2006-11-06 2016-05-18 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
JP5548365B2 (ja) 2006-11-08 2014-07-16 日本化薬株式会社 核酸系代謝拮抗剤の高分子誘導体
EP2115173B1 (en) 2007-01-08 2011-09-21 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Slco1b3 genotype
CZ200756A3 (cs) * 2007-01-23 2008-07-30 Heaton, A. S. Dvousložková farmaceutická kompozice obsahující taxan
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
CN101244053B (zh) * 2007-02-16 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 以多西他赛为主组分的新的分散体系
EP2146695A4 (en) * 2007-04-23 2010-05-19 Sun Pharmaceuticals Ind Ltd PHARMACEUTICAL COMPOSITIONS
CA2686225A1 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80
JP5349318B2 (ja) 2007-09-28 2013-11-20 日本化薬株式会社 ステロイド類の高分子結合体
CN101396354B (zh) * 2007-09-30 2010-12-01 江苏恒瑞医药股份有限公司 一种稳定的塔三烷类化合物液体组合物及其制备方法和其应用
WO2009047794A2 (en) * 2007-10-01 2009-04-16 Intas Pharmaceuticals Limited Taxane derivative composition
AR063111A1 (es) * 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
FR2922107B1 (fr) * 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
WO2009113983A1 (en) 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
WO2009113989A1 (en) 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
US8663643B2 (en) 2008-03-18 2014-03-04 Genentech, Inc. Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
EP2258397B1 (en) * 2008-03-18 2017-10-11 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of physiologically active substance
WO2009136572A1 (ja) 2008-05-08 2009-11-12 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
ES2344674B1 (es) * 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
JP5588983B2 (ja) 2008-08-11 2014-09-10 ウェルズ ファーゴ バンク ナショナル アソシエイション マルチアームポリマーアルカノエートコンジュゲート
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
MX2011009413A (es) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
CN102421827B (zh) 2009-05-15 2014-07-30 日本化药株式会社 具有羟基的生理活性物质的高分子结合体
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
DK2493466T3 (da) 2009-10-29 2021-04-26 Sanofi Mature Ip Hidtil ukendt antitumoral anvendelse af cabazitaxel
EA201200617A1 (ru) * 2009-11-23 2012-11-30 Серулин Фарма Инк. Полимеры на основе циклодекстрина для доставки лекарственных средств
TW201129380A (en) 2009-12-04 2011-09-01 Genentech Inc Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1
CN102791715B (zh) 2009-12-31 2016-04-27 卡洛斯三世国家癌症研究中心基金会 用作激酶抑制剂的三环化合物
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
EP2536720A1 (en) 2010-02-18 2012-12-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Triazolo [4, 5 - b]pyridin derivatives
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
CA2798180A1 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
EP2641605B1 (en) 2010-11-17 2018-03-07 Nippon Kayaku Kabushiki Kaisha Polymer derivative of cytidine metabolism antagonist
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
SG194045A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and abiraterone, and methods of use
KR101953210B1 (ko) 2011-05-19 2019-02-28 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ 단백질 키나아제 억제제로서의 대환식 화합물
WO2012156999A1 (en) 2011-05-19 2012-11-22 Manu Chaudhary Ready to use docetaxel formulation
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
PT2753355T (pt) 2011-09-08 2019-02-01 Univ New York Vírus herpes simplex oncolítico e suas utilizações terapêuticas
EP2754682B1 (en) 2011-09-11 2017-06-07 Nippon Kayaku Kabushiki Kaisha Method for manufacturing block copolymer
US9745631B2 (en) 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
CA2874521A1 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
NZ702244A (en) 2012-06-08 2017-06-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
WO2014014518A1 (en) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
EP2968406A4 (en) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai AUTOLOGOUS TUMOR LYSAT-FILLED DENDRITIC CELL VACCINE FOR THE TREATMENT OF LIVER CANCER
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
KR20160138177A (ko) 2014-03-21 2016-12-02 애브비 인코포레이티드 항-ｅｇｆｒ 항체 및 항체 약물 접합체
WO2015149006A2 (en) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
US10967015B2 (en) 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
CA3027103A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
AU2017277914A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
JP2019522643A (ja) 2016-06-08 2019-08-15 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
CA3027045A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
EP3679925B1 (en) 2017-09-07 2024-10-23 Shenzhen Salubris Pharmaceuticals Co. Ltd Pharmaceutical composition of docetaxel conjugate and preparation method
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4507217A (en) * 1983-03-07 1985-03-26 Lipid Specialties, Inc. Magnetic compositions and magnetic memory devices prepared therefrom
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.

Also Published As

Publication number Publication date
WO1994012171A1 (fr) 1994-06-09
TW271395B (es) 1996-03-01
GEP19991856B (en) 1999-12-06
EP0671912A1 (fr) 1995-09-20
AU691476B2 (en) 1998-05-21
FI113619B (fi) 2004-05-31
PL309197A1 (en) 1995-09-18
ES2145115T4 (es) 2010-06-17
FI952680A0 (fi) 1995-06-01
YU74593A (sh) 1996-08-13
PT671912E (pt) 2000-06-30
DE69328192D1 (de) 2000-04-27
MX9306986A (es) 1995-01-31
CZ284080B6 (cs) 1998-08-12
CN1636560A (zh) 2005-07-13
ZA938936B (en) 1994-08-03
PL174334B1 (pl) 1998-07-31
AU5566994A (en) 1994-06-22
YU49092B (sh) 2003-12-31
NZ258150A (en) 1996-11-26
DK0671912T3 (da) 2000-07-03
HK1075197A1 (en) 2005-12-09
NO952151D0 (no) 1995-05-31
FR2698543A1 (fr) 1994-06-03
HU222833B1 (hu) 2003-11-28
JP3689791B2 (ja) 2005-08-31
CA2150576A1 (fr) 1994-06-09
SK72595A3 (en) 1995-11-08
DE69328192T2 (de) 2000-09-28
HU9501596D0 (en) 1995-08-28
RU2144356C1 (ru) 2000-01-20
CN1291713C (zh) 2006-12-27
FI952680A (fi) 1995-06-01
EP0671912B1 (fr) 2000-03-22
KR100330316B1 (ko) 2002-11-04
ATE190838T1 (de) 2000-04-15
KR950703946A (ko) 1995-11-17
DE69328192T4 (de) 2007-07-19
JPH08503689A (ja) 1996-04-23
NO952151L (no) 1995-05-31
SK281558B6 (sk) 2001-05-10
HUT72650A (en) 1996-05-28
CA2150576C (fr) 2005-06-21
CZ142195A3 (en) 1995-10-18
CN1090170A (zh) 1994-08-03
FR2698543B1 (fr) 1994-12-30
US5438072A (en) 1995-08-01
GR3032828T3 (en) 2000-06-30
NO314436B1 (no) 2003-03-24

Similar Documents

Publication Publication Date Title
ES2145115T3 (es) Composiciones inyectables a base de derivados de taxanos.
ES2110003T3 (es) Nuevas composiciones a base de derivados de la clase de los taxanos.
HUP9900925A2 (hu) Napfényt szűrő készítmények
ES2142034T3 (es) Compuestos biaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ES2052881T3 (es) Agentes reductores de la presion sanguinea.
ES2083560T3 (es) Composicion detergente compacta que contiene polivinilpirrolidona.
ES2112140B1 (es) 3-arilbenzofuranonas como estabilizantes
ES2173284T3 (es) Agentes endoparasicitidas.
BR0211390A (pt) Tratamento de infecções da unha com no
DE69328072D1 (de) Umweltfreundliche Zusammensetzungen zur Verbesserung des Viskositätsindexes
ES2084073T3 (es) Aclarados finales libres de cromo para metal fosfatado.
MX9303159A (es) Agente para mejorar la maquinabilidad de productos concrecionados producidos a partir de fierro o acero.
CO4960655A1 (es) Nueva composicion y su uso
ES2175825T3 (es) Antitraspirante con dibencilidensorbitol.
ES2105551T3 (es) Utilizacion de derivados de la resorcina substituidos en posicion(es) 4,4 y 5 o 4 y 6 en unas composiciones cosmeticas o dermofarmaceuticas con accion despigmentante.
ES2187070T3 (es) Composiciones de laca para el cabello autofobas.
ES2182255T3 (es) Agente de blanqueo fluorescente.
MX9207504A (es) Composiciones curables por humedad y metodo para curar composiciones curables por humedad.
CO4920220A1 (es) Composiciones que contienen compuestos fluoroeter y metodos para inhibir su degradacion en presencia de un acido de lewis
ES2143734T3 (es) Compuestos bioaromaticos que llevan un grupo adamantilo en para, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
TR200100455T2 (tr) Nimesulid içeren topikal farmasötik bileşimler
CO5611210A2 (es) Composicion de jabon
ES2149036T3 (es) Sistema a base de derivado acido fosfonico y de metabisulfito para estabilizar el acido ascorbico.
ES2158077T3 (es) Carboxanilidas oxidiacinicas artropodicidas.
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 671912

Country of ref document: ES